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End-stage renal failure (ESRF) is a major and increasing health
problem, recently highlighted by the number of patients65 years
old who are now receiving hemodialysis access.1 The overall mor-
tality in patients on hemodialysis is significant, particularly in the
setting of peripheral vascular disease. Furthermore, the costs asso-
ciated with hemodialysis by itself, as well as the surgical complica-
tions, are significant. Thus, proper patient selection and choosing
the most durable hemodialysis access is important.
An excellent example of a consensus initiative changing prac-
tice has been the National Kidney Foundation Dialysis Outcome
and Quality Initiative (DOQI) guidelines. Specifically, increased
early referral by nephrologists to surgeons for hemodialysis access
placement, and second, promulgating the use of autologous vein
fistulas (AVFs) rather than AV grafts (AVGs) have gained wide-
spread support.
The current study retrospectively reviewed patients who un-
derwent an upper arm AVF compared with an AVG, and because
the patients were selected, its conclusions are somewhat biased.
For example, we are not told the overall number of patients whose
AVF failed to mature. Thus, candidacy for AVF compared with
AVGmay have selected for a healthier group of ESRF patients, and
the authors acknowledge this.
However, this paper is well written, has a wealth of data that
are rigorously analyzed, and the conclusions are sound. The data
herein confirmmy bias and also support the DOQI guidelines that
AVFs are significantly more durable and require fewer revisions
than AVGs.
Several themes stand out. First, those patients who had better
outcomes with AVFs were less likely to have a prior failed access,
and were less often female or African American.
Second, by multivariate regression analyses, hemodialysis-
dependence, history of prior upper arm access, and dialysis catheter
placement increase the risk of overall AVG failure. In a review from
our own institution, slightly lesser rates of assisted patency of
basilic vein AVGs (58% at 2 years) were documented.2 Of interest,
a prior ipsilateral venous catheter and prior access failure increased
the risk of AVG failure, consistent with the current article. These
data suggest that referring a patient early for an AVF and avoiding
an indwelling venous catheter may confer significant long-term
benefit. However, the exact timing is often difficult to estimate in
these patients, and an AVF placed too early has the potential to
thrombose or not mature.3
Third, the overall very poor secondary patency rate for AVGs
at 17% at 5 years is within my experience and underscores the poor
results from AVGs. The AVGs placed in this series were 6-mm
polytetrafluoroethylene, and a recent, randomized study showed
slightly better patency with a cuffed AVG at 1 year.4
Finally, 134 endovascular and 106 surgical revisions were
performed in the AVG group during the follow-up period. Signif-
icantly fewer were needed in the AVF cohort. The cost, both in
money and pain and suffering, is not delineated but is likely very
high for patients with AVGs. This fact is further emphasized by the
significantly greater infection and arterial steal incidence with
AVGs compared with AVFs.
Further questions remain to be addressed in these often very ill
patients. First, whether to proceed with an upper arm AVF rather
than a loop forearm AVG after a failed (or inability to place) wrist
AVF is an unanswered question. For example, whether a forearm
loop AVG burns a bridge for future upper arm AVF is not clear.
Second, the surgical technique and volume outcome-relation
with AV access has not been delineated, but may be quite impor-
tant. That is, if you lose a good AVF by poor operative technique,
the patient may end up suffering long term with repeated AVG
placements than if a technically satisfactory AVF is done. As with so
many things in surgery, your first shot is often your best shot.
Finally, better prognostication of patient longevity vs proce-
dure type needs to be done to choose the best hemodialysis access
for the patient. Some patients may have such a high likelihood of
short-term mortality that an indwelling catheter may be best.
Overall, this is an excellent study and supports not only the
DOQI recommendations but also puts forth further evidence that
AVF is superior to AVG in both early and long-term outcomes.
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